NuPathe (PATH) is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. This stock is trading up 9.2% at $4.01 in recent trading.
Today's Range: $3.76-$4.1252-Week Range: $1.52-$7.42 Volume: 150,000 Three-Month Average Volume: 30,648 Shares of PATH are moving notably higher today after the company said it expects acceptance of its resubmission of a migraine treatment by the U.S. Food and Drug Administration. >>5 Biotech Stocks Under $10 Set to Soar From a technical perspective, PATH is gapping up sharply here with above-average volume. This move is quickly pushing the stock within range of triggering a near-term breakout trade. That trade will hit once PATH takes out some near-term overhead resistance at $4.01 to $4.25 with high volume. Traders should now look for long-biased trades once PATH sustains a move or close above $4.01 to $4.25 with volume that's near or above 30,648 shares. At last check, PATH has hit an intraday high of $4.01 and volume is well above its three-month average of 30.648 shares. If that breakout triggers soon, then PATH will have a great chance of re-testing and possibly taking out its next major overhead resistance level at $5.10.